For Older Patients With CLL, Ibrutinib-Based Treatment Beats Standard Chemoimmunotherapy
Results from a randomized phase III study indicate that the Bruton tyrosine kinase (BTK) inhibitor ibrutinib with or without rituximab was superior to standard-of-care,...
Duvelisib Bests Ofatumumab in Relapsed and Refractory CLL/SLL
In the phase III DUO trial, treatment with the oral phosphoinositide 3-kinase (PI3K) dual inhibitor duvelisib improved progression-free survival (PFS) and overall response, compared...
Ibrutinib Versus FCR: A “Paradigm Shift” for Younger Patients With Treatment-Naïve CLL
In patients with previously untreated chronic lymphocytic leukemia (CLL), treatment with an ibrutinib-based therapy improved progression-free survival (PFS) and overall survival (OS), compared with...
Weighing Conditioning Regimens for Patients With CML Undergoing Transplant
Conditioning with a reduced-intensity, nonmyeloablative regimen was associated with similar post-transplant survival but a lower risk of chronic graft-versus-host disease (cGVHD), compared with a...
Higher Childhood Leukemia Risk in Offspring Raises Questions About Hormonal Contraceptive Safety
Children born to women who were using hormonal contraception within three months of pregnancy and during pregnancy have a higher risk of developing myeloid...
How I Treat In Brief: Managing Ibrutinib-Refractory Chronic Lymphocytic Leukemia
Jennifer A. Woyach, MD, associate professor at the Ohio State University Comprehensive Cancer Center, wrote about her strategy for the management of patients with...
Demystifying Epigenetics in Hematology
In the early 20th century, German researcher Theodor Boveri described the basic tenets of tumor biology: Cells can turn cancerous when they lose the...
Next Steps After TKIs for Patient With Chronic-Phase CML?
Here’s how readers responded to a You Make the Call question about the next steps after TKIs for patient with chronic-phase chronic myeloid leukemia.
Disclaimer:...
Next Steps After TKIs for Patient With Chronic-Phase CML?
This month, Michael Deininger, MD, PhD, discusses treatment for a patient with chronic-phase chronic myeloid leukemia (CML) whose BCR/ABL transcript levels are rising.
And don't...
Researchers Identify Cancer Gene Mutations Associated with Poor Outcomes in CML
Despite the good outcomes experienced by most patients with chronic-phase chronic myeloid leukemia (CP-CML) treated with tyrosine kinase inhibitors (TKIs), a subset do not...
Current Issue
August 2019, Volume 5, Issue 10
This issue features a debate about gun control as a health care issue, a look at blood services in Israel and Palestine, and more.
